钆磷维塞增强腋窝MRI对乳腺癌患者淋巴结(再)分期的诊断效能:一项验证研究结果
研究纳入90例新诊断乳腺癌患者,行腋窝T2加权及钆磷维塞增强MRI,两名放射科医师独立评分,以组织病理学为参考标准进行逐淋巴结和逐患者验证。逐患者验证中两种MRI的AUC相似(读者1为0.75 vs 0.77,p=0.731;读者2为0.79 vs 0.72,p=0.156);逐淋巴结验证中读者1的AUC从0.76提升至0.82(p=0.018)。结论认为钆磷维塞增强MRI联合T2加权MRI有潜力作为乳腺癌淋巴结(再)分期的无创方法。
要点
- 逐患者验证中,T2加权与钆磷维塞增强MRI的AUC相似,读者1为0.75 vs 0.77(p=0.731),读者2为0.79 vs 0.72(p=0.156)。
- 逐淋巴结验证中,读者1的AUC从T2加权0.76提升至钆磷维塞增强0.82(p=0.018),读者2均为0.77(p=0.998)。
- 读者1的AUC随评估节点数增加从首个三分之一0.71提升至后两个三分之一0.80和0.95,敏感度从38%升至60%。
核心结论
- 钆磷维塞增强MRI联合T2加权MRI有潜力作为乳腺癌淋巴结(再)分期的无创方法。
研究设计与样本
- 验证研究,纳入90例新诊断乳腺癌患者,行腋窝T2加权和钆磷维塞增强MRI,两名放射科医师独立评分,以组织病理学为参考标准进行逐淋巴结和逐患者验证,并分析阅读钆磷维塞增强MRI的学习曲线。
关键影像表现/征象
- 逐患者验证中,读者1的AUC在T2加权MRI为0.75、钆磷维塞增强MRI为0.77(p=0.731),读者2分别为0.79和0.72(p=0.156)。
- 逐淋巴结验证中,读者1的AUC在T2加权MRI为0.76、钆磷维塞增强MRI为0.82(p=0.018),读者2均为0.77(p=0.998)。
- 读者1的AUC在首个三分之一评估节点为0.71,后两个三分之一分别为0.80和0.95。
诊断标准与关键数值
- 读者1的敏感度、特异度、阳性预测值和阴性预测值从38%、89%、56%、79%提升至60%、93%、64%、92%。
- 读者2的AUC从0.69提升至0.79。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate diagnostic performance of gadofosveset (GDF)-enhanced magnetic resonance imaging (MRI) in addition to T2-weighted (T2W) MRI for nodal (re)staging in newly diagnosed breast cancer patients.
MATERIALS AND METHODS: Ninety patients underwent axillary T2W- and GDF-MRI. Two radiologists independently scored each lymph node; first on T2W-MRI, subsequently adjusting their score on GDF-MRI. Diagnostic performance parameters were calculated on node-by-node and patient-by-patient validation with histopathology as the reference standard. Furthermore, learning curve analysis for reading GDF-MRI was performed.
RESULTS: In patient-by-patient validation, overall reader performances for T2W- and GDF-MRI were similar with area under the receiver operating characteristic curves (AUC) of 0.75 and 0.77 (p=0.731) for reader 1 and 0.79 and 0.72 (p=0.156) for reader 2. For node-by-node validation, AUC values of T2W- and GDF-MRI were 0.76 and 0.82 (p=0.018) and 0.77 and 0.77 (p=0.998) for reader 1 and 2. The AUC for reader 1 was 0.71 for first one-third of nodes evaluated, improving to 0.80 and 0.95 for the next and last one-third, respectively. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) improved from 38%, 89%, 56%, and 79% to 60%, 93%, 64%, and 92%. The AUC of reader 2 improved from 0.69 to 0.79.
CONCLUSION: The present study confirmed that GDF-MRI, in addition to T2W-MRI, has potential as a non-invasive method for nodal (re)staging in breast cancer.
引用
- van Nijnatten TJA, Schipper RJ, Lobbes MBI, et al. Diagnostic performance of gadofosveset-enhanced axillary MRI for nodal (re)staging in breast cancer patients: results of a validation study. Clin Radiol. 2017. PMID: 29029766. doi:10.1016/j.crad.2017.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。